Renaissance Technologies’s Theravance Biopharma TBPH Stock Holding History

Renaissance Technologies’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.62M	Buy	154,318 +26,402	+21%	+$437K	﹤0.01%	1819
2026 Q1	$2.08M	Buy	+127,916	New	+$2.26M	﹤0.01%	1877
2023 Q1	–	Sell	-176,426	Closed	-$1.98M	–	4394
2022 Q4	$1.98M	Buy	176,426 +24,249	+16%	+$255K	﹤0.01%	2077
2022 Q3	$1.54M	Buy	+152,177	New	+$1.43M	﹤0.01%	2209
2020 Q1	–	Sell	-17,003	Closed	-$440K	–	3780
2019 Q4	$440K	Buy	+17,003	New	+$330K	﹤0.01%	2951
2018 Q2	–	Sell	-40,300	Closed	-$977K	–	3524
2018 Q1	$977K	Buy	+40,300	New	+$1.11M	﹤0.01%	2669
2016 Q1	–	Sell	-10,880	Closed	-$178K	–	3523
2015 Q4	$178K	Buy	+10,880	New	+$173K	﹤0.01%	3024
2015 Q3	–	Sell	-263,816	Closed	-$3.44M	–	3358
2015 Q2	$3.44M	Buy	+263,816	New	+$4.09M	0.01%	1688
2015 Q1	–	Sell	-14,086	Closed	-$210K	–	3340
2014 Q4	$210K	Buy	+14,086	New	+$245K	﹤0.01%	2683

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies's TBPH Position: Q2 2026 in Review

Renaissance Technologies increased its Theravance Biopharma (TBPH) stake by 21% in Q2 2026, buying an estimated $437K and bringing the position to 154,318 shares worth $2.62M. The position accounts for ﹤0.01% of the portfolio, ranked #1819.

Renaissance Technologies first reported a position in TBPH in Q4 2014 and has held it in 9 quarters since. The position peaked at $3.44M in Q2 2015. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Renaissance Technologies held 154,318 shares of Theravance Biopharma worth $2.62M as of Q2 2026.
Renaissance Technologies bought 26,402 Theravance Biopharma shares in Q2 2026, an estimated $437K.
Theravance Biopharma made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1819 holding.
Renaissance Technologies first reported a position in Theravance Biopharma in Q4 2014 and has held it in 9 quarters since.
Renaissance Technologies's Theravance Biopharma position peaked at $3.44M in Q2 2015.
181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.